Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials-Reference-Cited by-同舟云学术

Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials

Published:2020-04-29 Issue:11 Volume:16 Page:2628-2633
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Colindres Romulo¹²,Wascotte Valentine³^ORCID,Brecx Alain⁴^ORCID,Clarke Christopher³⁵^ORCID,Hervé Caroline³^ORCID,Kim Joon Hyung¹^ORCID,Levin Myron J.⁶^ORCID,Oostvogels Lidia³⁷^ORCID,Zahaf Toufik³^ORCID,Schuind Anne¹^ORCID,Cunningham Anthony L.⁸^ORCID

Affiliation:

1. GSK, Rockville, MD, USA

2. independent Biotech and Vaccines Consultant

3. GSK, Wavre, Belgium

4. GSK, Rixensart, Belgium

5. Seqirus, Victoria, Australia

6. Departments of Pediatrics and Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

7. CureVac AG, Tübingen, Germany

8. The Westmead Institute for Medical Research, University of Sydney, Sydney, Australia

Funder

GlaxoSmithKline Biologicals SA

Publisher